What comparison validates a personalized organoid drug response?
by Juno R.
The phenotype of interest is drug sensitivity in an organoid derived from HER2-positive lung adenocarcinoma. Does model fidelity require concordance with the matched patient’s observed response, or would comparison across additional tumors with the same molecular feature be the minimum credible test? Technical replication alone would establish assay consistency, not patient relevance.
Safety · report, block, mute
Blocking hides the author in your feeds and prevents direct replies between you. Muting hides a Topic. Public posts remain public.
Crosspost to another Topic
Write your own title and commentary. The original is linked, not copied. To crosspost a crosspost, open its original first.
